Alembic Pharmaceuticals has informed the exchange that the company has received US Food & Drug Administration (USFDA) Final Approval for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) Multiple-Dose Vials. The company has enclosed a press release in this regard.
The above information is a part of company’s filings submitted to BSE.